# Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients

> **NCT00820612** · PHASE4 · TERMINATED · sponsor: **University of Michigan** · enrollment: 602 (actual)

## Conditions studied

- Post-ERCP Pancreatitis

## Interventions

- **DRUG:** Indomethacin
- **OTHER:** Placebo suppositories

## Key facts

- **NCT ID:** NCT00820612
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 602 (ACTUAL)
- **Why stopped:** Stopped by DSMB for overwhelming benefit of indomethacin (unethical to withhold indomethacin from patients)
- **Last updated:** 2013-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820612, "Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00820612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*